Method for making multispecific antibodies having heteromultimeric and common components

• US 7,183,076 B2
• Filed: 05/10/2002
• Issued: 02/27/2007
• Est. Priority Date: 05/02/1997
• Status: Expired due to Fees

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Presta, Leonard G., Carter, Paul J., Arathoon, W. Robert, Merchant, Anne M.
• Primary Examiner(s): Rawlings; Stephen L.
• Application Number:
  US10/143,437
• Publication Number:
  US 20030078385A1
• Time in Patent Office: 1,754 Days
• Field of Search: 530/387.3, 435/69.1, 435/71.1, 435/328
• US Class Current: 435/69.1
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2812 against CD4
• CPC Class Codes: C07K 16/2869 against hormone receptors for antibodies against neuromediator receptors C07K16/286
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/31 multispecific
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C07K 2317/624 Disulfide-stabilized antibody (dsFv)
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method futher involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.

Claims

1. A method of preparing a bispecific antibody that specifically binds to a first and a second antigen, wherein said first and second antigens are different from one another, said method comprising:

(a) providing a first nucleic acid molecule encoding a first polypeptide comprising the variable region of a light chain of an antibody that binds said first antigen;

(b) providing a second nucleic acid molecule encoding a second polypeptide comprising the variable region of a heavy chain of said antibody that binds said first antigen;

(c) identifying and/or providing a third nucleic acid molecule encoding a third polypeptide comprising the variable region of a heavy chain, which, when paired with the light chain of said antibody that binds said first antigen, specifically binds to said second antigen;

(c) culturing a host cell comprising said first, second, and third nucleic acid molecules under conditions that permit formation of said bispecific antibody; and

(d) recovering said bispecific antibody.

2. A method according to claim 1, wherein said antibody that binds said first antigen is a chimeric or humanized antibody.

3. A method according to claim 1, wherein said antibody that binds said first antigen is a human antibody.

4. A method according to claim 1, wherein said variable region of the heavy chain, which when paired with the light chain of said antibody that binds said first antigen, specifically binds to said second antigen is chimeric or humanized.

5. A method according to claim 1, wherein said variable region of the heavy chain, which, when paired with the light chain of said antibody that binds said first antigen, specifically binds to said second antigen is fully human.

6. A method according to claim 1, wherein each of said second and third polypeptides encoded by said second and third nucleic acid molecules further comprises an antibody constant domain.

7. The method of claim 6, wherein said antibody constant domain is a C_H3 domain of a human IgG₁.

8. A method according to claim 1, wherein each of said second and third polypeptides encoded by said second and third nucleic acid molecules further comprises a multimerization domain, wherein said multimerization domains interact with one another forming an interface.

9. The method of claim 8, wherein each of said multimerization domains comprises a leucine zipper motif.

10. A method according to claim 8, further comprising engineering said second and/or third nucleic acid molecules to encode said second and third polypeptides, respectively, wherein the amino acid sequence of one, or both, of said multimerization domains is altered by the substitution of an amino acid at one position with a cysteine residue positioned to form a non-naturally occurring disulfide bond with a cysteine residue of the multimerization domain of the other of said second or third polypeptides at said interface.

11. A method according to claim 8, further comprising engineering said second and third nucleic acid molecules to encode said second and third polypeptides, respectively, wherein the amino acid sequence of the multimerization domain of said second polypeptide is altered by the substitution of an amino acid at one position with another amino acid having a larger side chain volume than the original amino acid and the amino acid sequence of the multimerization domain of said third polypeptide is altered by the substitution of an amino acid at one position with another amino acid having a smaller side chain volume than the original amino acid, wherein said amino acids having larger or smaller side chain volumes form a protuberance and a sterically compensatory cavity, respectively, at said interface.

12. The method of claim 11, wherein said amino acid having a larger side chain volume than the original amino acid is selected from the group consisting of tyrosine, arginine, phenylalanine, isoleucine, and tryptophan.

13. The method of claim 11, wherein said amino acid having a smaller side chain volume than the original amino acid is selected from the group consisting of alanine, glycine, valine and threonine.

14. A method of preparing a bispecific antibody that specifically binds to a first and a second antigen, wherein said first and second antigens are different from one another, said method comprising:

(a) identifying a first nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of the variable region of a light chain of an antibody that binds said first antigen, wherein the amino acid sequence of said light chain of an antibody that binds said first antigen is identical to the amino acid sequence of a light chain of another antibody that binds said second antigen;

(b) providing said first nucleic acid molecule;

(c) providing a second nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of the variable region of a heavy chain of said antibody that binds said first antigen;

(d) providing a third nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of the variable region of a heavy chain of said antibody that binds said second antigen;

(e) culturing a host cell comprising said first, second, and third nucleic acid molecules under conditions that permit formation of said bispecific antibody; and

(d) recovering said bispecific antibody.

15. A method according to claim 14, wherein each of said polypeptides encoded by said second and third nucleic acid molecules further comprises a multimerization domain, wherein said multimerization domains interact with one another forming an interface.

16. A method of preparing a bispecific antibody that specifically binds to a first and a second antigen, wherein said first and second antigens are different from one another, said method comprising:

(a) identifying a first nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of the variable region of a light chain of an antibody that binds said first antigen, wherein the amino acid sequence of said light chain of an antibody that binds said first antigen is identical to the amino acid sequence of a light chain of another antibody that binds said second antigen;

(b) providing a second nucleic acid molecule encoding a polypeptide comprising a light chain variable region comprising the three complementarity-determining regions (CDRs) of the light chain of said antibody that binds said first antigen, which, when paired with a heavy chain of said antibody that binds said first antigen specifically binds to said first antigen, and when paired with a heavy chain of said other antibody that binds said second antigen, specifically binds to said second antigen;

(c) providing a third nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of the variable region of a heavy chain of said antibody that binds said first antigen;

(d) providing a fourth nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of the variable region of a heavy chain of said other antibody that binds said second antigen;

(e) culturing a host cell comprising said second, third, and fourth nucleic acid molecules under conditions that permit formation of said bispecific antibody; and

(d) recovering said bispecific antibody.

17. An isolated host cell comprising:

(a) a first nucleic acid molecule encoding a first polypeptide comprising the variable region of a light chain of a first antibody that binds a first antigen;

(b) a second nucleic acid molecule encoding a second polypeptide comprising the variable region of a heavy chain of said first antibody;

(c) a third nucleic acid molecule encoding a third polypeptide comprising the variable region of a heavy chain of a second antibody that binds a second antigen;

wherein the first and second antigens are different from one another, and wherein said first polypeptide, when paired with said second polypeptide specifically binds to the first antigen, and when paired with said third polypeptide specifically binds to the second antigen, and wherein said first, second and third polypeptides interact to form a bispecific antibody that specifically binds to the first and second antigens.

18. The host cell of claim 17, wherein said first antibody that binds said first antigen is a chimeric or humanized antibody.

19. The host cell of claim 17, wherein said first antibody that binds said first antigen is a human antibody.

20. The host cell of claim 17, wherein said variable region of the heavy chain of said first antibody is chimeric or humanized.

21. The host cell of claim 17, wherein said variable region of the heavy chain of said first antibody is fully human.

22. The host cell of claim 17, wherein each of said second and third polypeptides encoded by said second and third nucleic acid molecules further comprises a multimerization domain, wherein said multimerization domains interact with one another forming an interface.

23. The host cell of claim 22, wherein each of said multimerization domains comprises a leucine zipper motif.

24. The host cell of claim 22, wherein the amino acid sequence of one, or both, of said multimerization domains is altered by the substitution of an amino acid at one position with a cysteine residue positioned to form a non-naturally occurring disulfide bond with a cysteine residue of the multimerization domain of the other of said second or third polypeptide at said interface.

25. The host cell of claim 22, wherein the amino acid sequence of the multimerization domain of said second polypeptide is altered by the substitution of an amino acid at one position with another amino acid having a larger side chain volume than the original amino acid and the amino acid sequence of the multimerization domain of said third polypeptide is altered by the substitution of an amino acid at one position with another amino acid having a smaller side chain volume than the original amino acid, wherein said amino acids having larger or smaller side chain volumes form a protuberance and a sterically compensatory cavity, respectively, at said interface.

26. The host cell of claim 25, wherein said amino acid having a larger side chain volume than the original amino acid is selected from the group consisting of tyrosine, arginine, phenylalanine, isoleucine, and tryptophan.

27. The host cell of claim 25, wherein said amino acid having a smaller side chain volume than the original amino acid is selected from the group consisting of alanine, glycine, valine, and threonine.

28. An isolated host cell comprising:

(a) a first nucleic acid molecule encoding a first polypeptide comprising a light chain variable region comprising the three complementarity-determining regions (CDRs) of a light chain of an antibody that binds a first antigen;

(b) a second nucleic acid molecule encoding a second polypeptide comprising the variable region of a heavy chain of the antibody that binds the first antigen;

(c) a third nucleic acid molecule encoding a third polypeptide comprising the variable region of a heavy chain of an antibody that binds a second antigen;

wherein the first and second antigens are different from one another, and wherein said first polypeptide, when paired with said second polypeptide specifically binds to the first antigen, and when paired with said third polypeptide specifically binds to the second antigen, and wherein said first, second and third polypeptides interact to form a bispecific antibody that specifically binds to the first and second antigens.

29. The host cell of claim 28, wherein said antibody that binds said first antigen is a chimeric or humanized antibody.

30. The host cell of claim 28, wherein said antibody that binds said first antigen is a human antibody.

31. The host cell of claim 28, wherein said variable region of a heavy chain of the antibody that binds the first antigen is chimeric or humanized.

32. The host cell of claim 28, wherein said variable region of a heavy chain of the antibody that binds the first antigen is fully human.

33. The host cell of claim 28, wherein each of said second and third polypeptides encoded by said second and third nucleic acid molecules further comprises a multimerization domain, wherein said multimerization domains interact with one another forming an interface.

34. The host cell of claim 33, wherein each of said multimerization domains comprises a leucine zipper motif.

35. The host cell of claim 33, wherein the amino acid sequence of one, or both, of said multimerization domains is altered by the substitution of an amino acid at one position with a cysteine residue positioned to form a non-naturally occurring disulfide bond with a cysteine residue of the multimerization domain of the other of said second or third polypeptide at said interface.

36. The host cell of claim 33, wherein the amino acid sequence of the multimerization domain of said second polypeptide is altered by the substitution of an amino acid at one position with another amino acid having a larger side chain volume than the original amino acid and the amino acid sequence of the multimerization domain of said third polypeptide is altered by the substitution of an amino acid at one position with another amino acid having a smaller side chain volume than the original amino acid, wherein said amino acids having larger or smaller side chain volumes form a protuberance and a sterically compensatory cavity, respectively, at said interface.

37. The host cell of claim 36, wherein said amino acid having a larger side chain volume than the original amino acid is selected from the group consisting of tyrosine, arginine, phenylalanine, isoleucine, and tryptophan.

38. The host cell of claim 36, wherein said amino acid having a smaller side chain volume than the original amino acid is selected from the group consisting of alanine, glycine, valine, and threonine.